Some PH patients with interstitial lung disease may benefit from oral PAH drugs
- PHA Canada
- Apr 14, 2025
- 1 min read
Medications for pulmonary arterial hypertension (PAH) are not approved for use in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD, part of Group 3 PH). This study looked at whether PH-ILD patients benefited from PAH medications. They found no benefit to patients' functional class, pulmonary function tests, or six-minute walk distances, but they did see improvements in NT-proBNP (a measure of heart function) and blood flow. This study was too small to do so but, in future, precision medicine may be able to identify PH-ILD patients who may benefit from PAH drugs.
It is fascinating to see research in which oral PAH drugs can be of benefit to patients suffering from interstitial lung disease. The developments in NT-proBNP and blood flow are indications for really future-targeted therapies, although the study itself did not show benefit in some areas. Remember, if you are feeling bogged down with studies or research in this area, seeking the best PhD thesis help can make all the difference!